Oxford Biomedica/£OXB
1D1W1MYTD1Y5YMAX
Capital at risk
About Oxford Biomedica
- Ticker
- £OXB
- Sector
- Health
- Primary listing
- LSE
- Employees
- 977
- Headquarters
- Oxford, United Kingdom
- Website
- www.oxb.com
Oxford Biomedica Metrics
BasicAdvanced
£537M
-
-£0.27
1.09
-
Price and volume
Market cap
£537M
Beta
1.09
52-week high
£9.62
52-week low
£4.20
Average daily volume
961K
Financial strength
Current ratio
2.204
Quick ratio
1.924
Long term debt to equity
155.531
Total debt to equity
162.161
Interest coverage (TTM)
-2.35%
Profitability
EBITDA (TTM)
-19.562
Gross margin (TTM)
39.10%
Net profit margin (TTM)
-17.85%
Operating margin (TTM)
-19.20%
Effective tax rate (TTM)
4.04%
Revenue per employee (TTM)
£170,000
Management effectiveness
Return on assets (TTM)
-6.97%
Return on equity (TTM)
-40.37%
Valuation
Price to revenue (TTM)
2.942
Price to book
5.86
Price to tangible book (TTM)
8.09
Price to free cash flow (TTM)
-116.686
Free cash flow yield (TTM)
-0.86%
Free cash flow per share (TTM)
-0.038
Growth
Revenue change (TTM)
31.01%
Earnings per share change (TTM)
-35.52%
3-year revenue growth (CAGR)
6.42%
10-year revenue growth (CAGR)
26.64%
3-year earnings per share growth (CAGR)
-13.29%
10-year earnings per share growth (CAGR)
0.61%
What the Analysts think about Oxford Biomedica
Analyst ratings (Buy, Hold, Sell) for Oxford Biomedica stock.
Analyst projections of the future price of Oxford Biomedica stock.
Bulls say / Bears say
Revenue grew 33% to £168.7 million in FY 2025 and OXB achieved an Operating EBITDA profit of £8.1 million, reversing a prior £15.3 million loss and meeting the upper end of guidance (Reuters).
Revenue backlog rose c.36% to £204 million and contracted client orders increased c.20% to £224 million as of 31 December 2025, underpinning strong revenue visibility into 2026 (Reuters).
OXB signed a new multi-year commercial supply agreement with Bristol Myers Squibb to manufacture lentiviral vectors for BMS’s CAR-T programmes, with a five-year initial term and extension option, securing meaningful multi-year revenue (Reuters).
OXB cut its FY2026 revenue guidance to £180–200 million from £220–240 million, citing operational delays at its Durham, NC facility and deferred client orders, marking a ~17% reduction in top-line expectations (Reuters).
Management warned of an EBITDA loss in H1 2026 due to planned maintenance shutdowns and integration costs at the Durham facility, delaying profit delivery to the second half of the year (Reuters).
OXB attributed the guidance cut to changes in client ordering behaviour, including delayed programme timelines and altered procurement pathways, highlighting demand volatility and revenue timing risk (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2026.
Oxford Biomedica Financial Performance
Revenues and expenses
Oxford Biomedica Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Oxford Biomedica
AllGBPUSDEUR
Fund name | Fund size | £OXB weighting |
|---|---|---|
Vanguard FTSE 250£VMID | £1.6B | 0.14% |
iShares FTSE 250£MIDD | £661M | 0.11% |
iShares Healthcare Innovation$HEAL | $1.4B | 0.08% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.08% |
iShares Healthcare Innovation£DRDR | £1B | 0.08% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.